(T3) and Thyroxine (T4) in the Human Choriocarcinoma Cell Line

Total Page:16

File Type:pdf, Size:1020Kb

(T3) and Thyroxine (T4) in the Human Choriocarcinoma Cell Line 487 Different transporters for tri-iodothyronine (T3) and thyroxine (T4)in the human choriocarcinoma cell line, JAR K A Powell1, A M Mitchell1, S W Manley2 and R H Mortimer1,3 1Conjoint Endocrine Laboratory, Royal Brisbane Hospital Research Foundation, The Bancroft Centre, 300 Herston Road, Brisbane, Queensland 4029, Australia 2Department of Physiology, The University of Queensland, Queensland 4072, Australia 3Department of Pharmacology, Obstetrics and Gynaecology, The University of Queensland, Queensland 4072, Australia (Requests for offprints should be addressed to K A Powell; Email: [email protected]) Abstract We investigated transport systems for tri-iodothyronine In contrast, the Km for T3 uptake was increased from (T3) and thyroxine (T4) in the human choriocarcinoma a control value of around 300 nM to around 750 nM cell line, JAR, using a range of structurally similar com- (n=4). Diazepam had similar effects. This divergent ffi pounds to determine whether these thyroid hormones shift in a nity for the uptake of T3 and T4 suggested are transported by common or different mechanisms. that separate uptake systems exist for these two thyroid Saturable T3 but not saturable T4 uptake was inhibited hormones. by a wide range of aromatic compounds (nitrendipine, This provides evidence for at least two transporters nifedipine, verapamil, meclofenamic acid, mefenamic mediating uptake of T3 and T4 in JAR cells: a specific T4 acid, diazepam, phenytoin). transporter that does not interact with T3 or structurally Nitrendipine and diazepam were the most similar compounds; and a shared iodothyronine transporter ff e ective inhibitors of saturable thyroid hormone uptake. that interacts with T3,T4, nitrendipine and diazepam. Nitrendipine decreased the Km for T4 uptake from a Journal of Endocrinology (2000) 167, 487–492 control value of around 500 nM to around 300 nM (n=6). Introduction synaptosomes and cardiac myocytes (Kragie 1994 (re- view), Everts et al. 1996) actively transport T3 while T4 is ff Although transfer of thyroxine (T4) from maternal to foetal probably taken up by simple di usion. Separate transport circulation in the perfused placenta is minimal (Mortimer mechanisms for T3,T4 and rT3 have been described in et al. 1996), T4 has been found in cord blood of infants human liver (Kaptein 1997) and separate membrane unable to synthesise their own hormone (Vulsma et al. transporters mediating uptake of T3 and T4 are also 1989). While this provides convincing evidence for the suggested for rat hepatocytes (Krenning et al. 1981). These passage of maternal thyroid hormone across the placenta, at findings taken together suggest that the processes involved least to a foetus lacking thyroid hormone, the mechanisms in uptake and efflux of thyroid hormones may be relatively mediating this transfer are not well understood. specific for individual thyroid hormones and may be We have previously described membrane transporters different depending on tissue type. for thyroid hormones in human trophoblast and the Our previous studies have shown that thyroid hormones human choriocarcinoma cell line, JAR. Transport of are taken up into JAR cells by at least two transporters ff ffi tri-iodothyronine (T3), T4 and reverse tri-iodothyronine with di ering a nities (Mitchell et al. 1999a,b). The aim (rT3) into JAR cells and export of T3 from the cells occurs of this study was to determine if T3 and T4 were ffl by saturable processes. E ux of T4 and rT3, on the other transported by a distinct or shared mechanism in order to hand, occurs by passive diffusion (Mitchell et al. 1992, further characterise iodothyronine transport in JAR cells. 1995, 1999a,b). Membrane transport of thyroid hormone has now been characterised in a wide range of cells, with Materials and Methods reported differences in thyroid hormone uptake and efflux kinetics between and within cell types. In hepatocytes, Reagents for example, uptake of T3 is energy dependent and ffl ff T3 e ux occurs by passive di usion (Hennemann et al. Materials were purchased from the following sources: 125 125 1984). Human and rat lymphocytes and erythrocytes, rat I-T3 (3300 µCi/µg) and I-T4 (1250 µCi/µg) from Journal of Endocrinology (2000) 167, 487–492 Online version via http://www.endocrinology.org 0022–0795/00/0167–487 2000 Society for Endocrinology Printed in Great Britain Downloaded from Bioscientifica.com at 09/26/2021 12:17:42AM via free access 488 K A POWELL and others · Specific thyroxine transporter in JAR cells Du Pont Company, Wilmington, DE, USA; foetal calf reactive red, reactive blue, acid blue and 50 µM iopanoic serum from Commonwealth Serum Laboratories, acid. Drugs and dyes were dissolved in ethanol and diluted Melbourne, Victoria, Australia; bicinchoninic acid Protein in HBSS. The final concentration of ethanol did not ff Reagent from Pierce Chemicals, Rockford, IL, USA; and exceed 0·4%, which had no e ect on cellular uptake of T3 six-well tissue culture plates from Costar, Cambridge, or T4. Results from three to seven determinations were MA, USA. All other chemicals and cell culture media pooled. Further characterisation of the transport system were from Sigma Chemicals, St Louis, MO, USA. was carried out using inhibitor studies to determine the Nitrendipine was a gift from Bayer Pharmaceutical kinetic parameters of inhibition of thyroid hormone Division, West Haven, CO, USA. uptake by various compounds. The cells were incubated 125 for 2 min in the presence of 30 pM I-T3 or 50 pM 125 I-T4 and unlabelled T3 and T4 (0–10 µM) with or Cell culture without 100 µM final concentration of unlabelled The JAR cell line was purchased from American Type nitrendipine and 80–100 µM final concentration of Culture Collection, Rockville, MD, USA. Cells were diazepam. Results from 4–8 determinations were pooled maintained in continuous culture at 37 C in humidified and data fitted to the Michaelis–Menten equation using atmosphere of 95% air and 5% CO2. Growth medium was a non-linear curve-fitting program (GraphPad Prism, RPMI 1640 supplemented with 10% (v/v) foetal calf GraphPad, San Diego, CA, USA). 125 serum. Cells were subcultured three times a week. We sought evidence of metabolism of I-T3 and 5 125 For uptake experiments, 3 10 cells were plated into I-T4 by duplicate cultures of JAR cells during uptake each well of the six-well tissue culture plates. Medium experiments by analysing radioactivity present in the cells was changed 24 h after plating, with cells cultured for and in the medium after incubation with the tracers for 2–3 days. At the end of the uptake experiments, viability 30 min at 37 C. As in our previous studies, we found of the cells was assessed by the trypan blue exclusion test evidence of only minimal metabolism of tracers by the and was always over 90%. cells. Uptake studies Determination of the cellular protein content The procedure for uptake studies and the determination of The protein content of cell lysates was determined with the kinetic parameters (Michaelis constant, Km, and the the bicinchoninic acid reagent (Pierce Chemicals) which maximum velocity, Vmax) of the initial cellular uptake of isamodification of the Biuret reaction using BSA as a 125 125 I-T3 and I-T4 were as previously described (Mitchell standard. et al. 1992, 1995). In brief, prior to all uptake experiments cells were incubated for 1 h in Hanks’ balanced salts solution (HBSS). All incubations were carried out at Statistical analysis 37 C. To terminate uptake, incubation medium was Statistical analysis was performed by Student’s t-test and aspirated, cells were washed twice in ice-cold HBSS and one-way ANOVA followed by multiple comparison of immediately lysed in 1 M NaOH. Cell-associated radio- means against a single control (Bonferonni’s t-test) using activity was determined by counting the radioactivity in a the statistical software package SigmaStat (Jandel Scien- Packard -counter with a counting efficiency of 84%. tific, San Rafael, CA, USA). Results were expressed as 125I-labelled thyroid hormone taken up was expressed as means and standard errors of the mean, and n is the femtomoles per minute per milligram of cellular protein number of independent determinations, each in triplicate. (fmol/min per mg protein). The specificity of the A probability of <0·05 was regarded as significant. uptake process was examined by incubating cells for 125 30 min in the presence of 30 pM I-T3 or 50 pM 125 I-T4, with or without 10 µM excess of unlabelled Results thyroid hormones, 10 mM unlabelled amino acids, 125 125 tryptophan, phenylalanine, leucine, glycine, alanine, Uptake of I-T3 and I-T4 in JAR cells was inhibited glutamine, -(methylamino)-isobutyric acid (Me-AIB) by the L-system amino acids tryptophan, phenylalanine, and 2-amino-2-norbornane-carboxylic acid (BCH). The leucine and the synthetic amino acid analogue 2-amino- effect of various compounds on the initial rate of specific 2-norbornane-carboxylic acid (BCH). Tryptophan was ff 125 uptake of thyroid hormone was determined by incubating the most e ective inhibitor, reducing saturable I-T3 125 125 cells for 2 min in the presence of 30 pM I-T3 or 50 pM and I-T4 uptake by 85·5% (n=3) and 63·6% (n=4) 125 ff I-T4 with or without 10 µM unlabelled thyroid respectively. The e ects of L-system amino acids on hormone and with or without 100 µM nitrendipine, thyroid hormone uptake are shown in Fig. 1. Amino acids nifedipine, verapamil, meclofenamic acid mefenamic acid, transported by other amino acid carriers had no significant ff diazepam, phenytoin, indocyanine green, procion red, e ect on the uptake of T3 and T4 (results not shown). Journal of Endocrinology (2000) 167, 487–492 www.endocrinology.org Downloaded from Bioscientifica.com at 09/26/2021 12:17:42AM via free access Specific thyroxine transporter in JAR cells · K A POWELL and others 489 Figure 1 Effect of amino acids on the saturable uptake of 125 125 (A) I-T3 (n=3–4) and (B) I-T4 (n=4–7) in JAR cells.
Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • An Advanced Drug Delivery System Targeting Brain Through BBB
    pharmaceutics Review Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB Mantosh Kumar Satapathy 1 , Ting-Lin Yen 1,2,† , Jing-Shiun Jan 1,†, Ruei-Dun Tang 1,3, Jia-Yi Wang 3,4,5 , Rajeev Taliyan 6 and Chih-Hao Yang 1,5,* 1 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] (M.K.S.); [email protected] (T.-L.Y.); [email protected] (J.-S.J.); [email protected] (R.-D.T.) 2 Department of Medical Research, Cathay General Hospital, Taipei 22174, Taiwan 3 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] 4 Department of Neurosurgery, Taipei Medical University Hospital, Taipei 110, Taiwan 5 Neuroscience Research Center, Taipei Medical University, Taipei 110, Taiwan 6 Department of Pharmacy, Neuropsychopharmacology Division, Birla Institute of Technology and Science, Pilani 333031, India; [email protected] * Correspondence: [email protected]; Tel.: +886-2-2736-1661 (ext. 3197) † These authors contributed equally to this work. Abstract: The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among Citation: Satapathy, M.K.; Yen, T.-L.; some of the limitations associated with current neurotherapeutics.
    [Show full text]
  • Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R
    Article Cite This: Cryst. Growth Des. 2019, 19, 4101−4108 pubs.acs.org/crystal In the Context of Polymorphism: Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R. Vazqueź Marrero, , Carmen Piñero Berríos, , Luz De Dios Rodríguez, , ‡ ∥ ‡ § Torsten Stelzer,*, , and Vilmalí Lopez-Mej́ ías*, , † Department of Biology, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ‡ Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States § Department of Chemistry, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ∥ Department of Pharmaceutical Sciences, University of Puerto RicoMedical Sciences Campus, San Juan, Puerto Rico 00936, United States *S Supporting Information ABSTRACT: Solubility measurements for polymorphic com- pounds are often accompanied by solvent-mediated phase transformations. In this study, solubility measurements from undersaturated solutions are employed to investigate the solubility of the two most stable polymorphs of flufenamic acid (FFA forms I and III), tolfenamic acid (TA forms I and II), and the only known form of niflumic acid (NA). The solubility was measured from 278.15 to 333.15 K in four alcohols of a homologous series (methanol, ethanol, 1- propanol, n-butanol) using the polythermal method. It was established that the solubility of these compounds increases with increasing temperature. The solubility curves of FFA forms I and III intersect at ∼315.15 K (42 °C) in all four solvents, which represents the transition temperature of the enantiotropic pair. In the case of TA, the solubility of form II could not be reliably obtained in any of the solvents because of the fast solvent- mediated phase transformation.
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • Formulation and Evaluation of Nitrendipine Buccal Films
    www.ijpsonline.com SShorthort CCommunicationsommunications Formulation and Evaluation of Nitrendipine Buccal Films M. NAPPINNAI*, R. CHANDANBALA AND R. BALAIJIRAJAN Department of Pharmaceutics, C. L. Baid Mehta College of Pharmacy, Jyothi Nagar, Thoraipakkam, Old Mahabalipuram Road, Chennai-600 096, India Nappinnai, et al.: Nitrendipine buccal fi lms A mucoadhesive drug delivery system for systemic delivery of nitrendipine, a calcium channel blocker through buccal route was formulated. Mucoadhesive polymers like hydroxypropylmethylcellulose K-100, hydroxypropylcellulose, sodium carboxymethylcellulose, sodium alginate, polyvinyl alcohol, polyvinyl pyrrolidone K-30 and carbopol- 934P were used for fi lm fabrication. The fi lms were evaluated for their weight, thickness, percentage moisture absorbed and lost, surface pH, folding endurance, drug content uniformity, In vitro residence time, In vitro release and ex vivo permeation. Based on the evaluation of these results, it was concluded that buccal fi lms made of hydroxylpropylcellulose and sodium carboxymethylcellulose (5±2% w/v; F-4), which showed moderate drug release (50% w/w at the end of 2 h) and satisfactory fi lm characteristics could be selected as the best among the formulations studied. Key words: Buccal fi lms, carboxymethylcellulose, hydroxylpropylcellulose, nitrendipine Mucoadhesive drug delivery systems may be bioadhesive polymers was executed. formulated to adhere to the mucosa of eyes, nose, oral (buccal), intestine, rectum and vagina1. Among these Nitrendipine (NTD) was obtained as a gift systems, the buccal mucosa offers many advantages sample from M/s. Camlin Ltd., Mumbai. like relatively large surface area of absorption, easy Hydroxypropylmethylcellulose K-100 (HPMC accessibility, simple delivery devices, avoiding hepatic K-100) and hydroxypropylcellulose (HPC) were first pass metabolism and feasibility of controlled purchased from Lab Chemicals, Chennai.
    [Show full text]
  • The Effect of Nitrendipine and Levetiracetam in Pentylenetetrazole Kindled Rats Meryem Dilek Karakurt1, Süleyman Emre Kocacan2, Cafer Marangoz3
    Meryem Dilek Karakurt et al., IJNR, 2019; 3:9 Research Article IJNR (2019) 3:9 International Journal of Neuroscience Research (ISSN:2572-8385) The Effect of Nitrendipine and Levetiracetam in Pentylenetetrazole Kindled Rats Meryem Dilek Karakurt1, Süleyman Emre Kocacan2, Cafer Marangoz3 1Ankara Yıldırım Beyazıt University Medical Faculty, Ankara, TURKEY 2Ondokuz Mayıs University Medical Faculty, Samsun, TURKEY 3Istanbul Medipol University Medical Faculty, Istanbul, TURKEY ABSTRACT We aimed to investigate the efficacy of L-type voltage gated Abbrevations: calcium channel blocker nitrendipine and levetiracetam in PTZ: Pentylenetetrazol; DMSO: pentylenetetrazole (PTZ) kindled male rats. In order to establish Dimethyl sulfoxide; sc: Second; kindling model, 35 mg/kg PTZ injected intraperitoneally (i.p.) EEG: Electroencephalography; to male wistar albino rats three days a week. Then, screw mV: Milivolt; electrodes were placed in the skulls of the kindled rats. During the experiments, EEG activities and seizure behaviors of kindled *Correspondence to Author: rats were recorded. The kindled rats were divided into control Meryem Dilek Karakurt (n=6), PTZ (n=6), nitrendipine (2.5 mg/kg (n=6), 5 mg/kg (n=6), Ankara Yıldırım Beyazıt University 10 mg/kg (n=6)) and levetiracetam (10 mg/kg (n=6), 20 mg/ Medical Faculty, Physiology De- kg (n=6), 40 mg/kg (n=6)) groups. Nitrendipine (5 mg/kg) and partment, 06010 Ankara, TURKEY levetiracetam (20 mg/kg) were suppressed the spike frequency and the seizure score effectively (p<0.05). The effective doses How to cite this article: of nitrendipine (5 mg/kg) and levetiracetam (20 mg/kg) were Meryem Dilek Karakurt, Süleyman administered consecutively to the kindled animals (n=6).
    [Show full text]
  • Original Article
    Journal of Human Hypertension (2003) 17, 487–493 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Nitrendipine and amlodipine mimic the acute effects of enalapril on renal haemodynamics and reduce glomerular hyperfiltration in patients with chronic kidney disease LF Morrone, A Ramunni, E Fassianos, A Saracino, P Coratelli and G Passavanti Section of Nephrology, Department of Internal Medicine and Public Medicine, University of Bari, Polyclinic, Piazza G. Cesare, Bari, Italy Antihypertensive drugs may have an important effect on and NIT test dose reduced FF, as did ENA, but not NIF, glomerular haemodynamics. In chronic nephropathy in both baseline (AML: P ¼ 0.005; NIT: P ¼ 0.02; ENA: patients, we compared the effect on glomerular haemo- P ¼ 0.007) and glomerular hyperfiltration conditions dynamics of two second-generation dihydropyridinic (AML: P ¼ 0.0003; NIT: P ¼ 0.03; ENA: P ¼ 0.00006). In agents, nitrendipine and amlodipine, with a first genera- baseline conditions, only ENA resulted in a significant tion dihydropyridinic agent and an ACE-inhibitor, en- drop in the GFR (P ¼ 0.008), while NIF, NIT and AML alapril. In all, 32 patients (pts), divided into four groups, induced a significant increase (P ¼ 0.003, 0.03, 0.0001, received the different drugs: ENA (enalapril, eight pts), respectively). However, in hyperfiltration conditions, NIT NIF (nifedipine, eight pts), NIT (nitrendipine, eight pts) (0.08) and AML (0.00003) caused a decrease in the GFR, AML (amlodipine, eight pts). The study assessed the as did ENA (0.0003) but not NIF. In all the experimental effect on glomerular haemodynamics of a single admin- conditions, a RVR reduction and an ERPF increase were istration of the test drug in baseline conditions and in observed.
    [Show full text]
  • Government Gazette
    Government Gazette REPUBLIC OF SOUTH AFRICA Regulation Gazette No. 7636 Vol. 454 Pretoria 10 April 2003 No. 24727 AIDS HELPLINE: 0800-0123-22 Prevention is the cure I STAATSKOERANT, 10 APRIL 2003 No. 24727 3 GOVERNMENT NOTICES GOEWERMENTSKENNISGEWINGS DEPARTMENT OF HEALTH DEPARTEMENT VAN GESONDHEID NO. R. 509 10 April 2003 SCHEDULES The Minister of Health has, in terms of section 22A(2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the Medicines Control Council, made the Schedulesin the Schedule SCHEDULE I In these Schedules, "the Act" meansthe Medicines and Related SubstancesAct, 1965 (Act No. 101 of 1965) SCHEDULE 0 (a) All substancesreferred to in thisSchedule are excluded when specifically packed, labelled and usedfor - (i) industrialpurposes including the manufacture or compounding of consumer items or products which have no pharmacological oraction medicinal purpose, which are intended to be ingested by man or animals as food, or applied to the body as a cosmetic, and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972) or registeredin terms of theFertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947); and (ii)analytical laboratory purposes. (b) All substances referred to in this Schedule include the following: 4 No. 24727 GOVERNMENT GAZETTE, 10 APRIL 2003 (i) The saltsand esters of suchsub2ances,+vhere the existence of such salts and esters is possible; and (ii) All preparationsand mixtures of suchsubstances where such preparations and mixtures arenot expressly excluded. This Schedule includesall substances subject to registration in termsof the Act and which are not listed in anyof the other Schedules.
    [Show full text]
  • Substance Abuse
    \1\A-10/PSA/93.10 ORIGINAL: ENGUSH DISTR.: GENERAL PROGRAMME ON SUBSTANCE ABUSE Approaches to Treatment of Substance Abuse WORLD HEALTH ORGANIZATION ABSTRACf The aim of this report is to provide an updated description of different methods used around the world to treat health problems associated with substance use. The scope of treatment approaches currently practised around the world is wide, ranging from traditional healing practices via mutual self-help groups, psychological/behavioural treatment to pharmacological treatment. Also included is a chapter on the generalist responses to alcohol and other drug problems and a chapter on the concept of harm minimization. Another aspect is a chapter on specific descriptors, which distinguishes different treatments from one another and provides economic means of describing them. Social and structural extra-treatment factors influencing the treatment process are also a subject described in this report. ©World Health Organization, 1993 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. ii CONTENTS page Acknowledgements . v Introduction . 1 I. Descriptors of Treatments . 3 11. Factors Influencing Treatment . 31 Ill. Generalist Responses to Alcohol and other Drug Problems . 53 IV. Pharmacological Treatment of Dependence on Alcohol and other Drugs: An Overview . 75 V. Psychological, Behavioural and Psychodynamic Treatments for Substance Abuse . 103 VI.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A Unitary Mechanism of Calcium Antagonist Drug Action '(Dihydropyridine/Nifedipine/Verapamil/Neuroleptic/Diltiazem) KENNETH M
    Proc. Nati Acad. Sci. USA Vol. 80, pp. 860-864, February 1983 Medical Sciences A unitary mechanism of calcium antagonist drug action '(dihydropyridine/nifedipine/verapamil/neuroleptic/diltiazem) KENNETH M. M. MURPHY, ROBERT J. GOULD, BRIAN L. LARGENT, AND SOLOMON H. SNYDER* Departments of Neuroscience, Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 72S North Wolfe Street, Baltimore, Maryland 21205 Contributed by Solomon H. Snyder, October 21, 1982 ABSTRACT [3H]Nitrendipine binding to drug receptor sites liquid scintillation counting were carried out as described (7). associated with calcium channels is allosterically regulated by a All experiments, performed in triplicate, were replicated at diverse group of calcium channel antagonists. Verapamil, D-600 least three times with similar results. (methoxyverapamit), tiapamil, lidoflazine, flunarizine, cinnari- Guinea pig ileum longitudinal muscles were prepared for zine, and prenylamine all reduce P3H]nitrendipine binding affin- recording as described by Rosenberger et aL (13) and incubated ity. By contrast, diltiazem, a benzothiazepine calcium channel an- in a modified Tyrode's buffer (14) at 370C with continuous aer- tagonist, enhances [3H]nitrendipine binding. All these drugeffects ation with 95% '02/5% CO2. Ileum longitudinal muscles were involve a single site allosterically linked to the [3H]nitrendipine incubated in this buffer for 30 min before Ca2"-dependent con- binding site. Inhibition of t3H]nitrendipine binding by prenyl- were as described Jim et aL amine, lidoflazine, or tiapamil is reversed by D-600and diltiazem, tractions recorded by (15). which alone respectively slightlyreduceorenhance H]mnitrendipine RESULTS binding. Diltiazem reverses the inhibition of [3H]nitrendipine binding by D-600.
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]